Fractyl Health (NASDAQ:GUTS) Given New $4.00 Price Target at Morgan Stanley

Fractyl Health (NASDAQ:GUTS – Get Free Report) had its price objective dropped by Morgan Stanley to $4.00 in a report issued on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley‘s target price suggests a potential upside of 239.85% from the company’s current price.

Other equities analysts have also issued reports about the stock. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Craig Hallum set a $5.00 price target on Fractyl Health in a research report on Monday. Finally, Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $50.25.

Read Our Latest Stock Report on GUTS

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS traded up $0.03 during trading on Monday, hitting $1.18. 347,228 shares of the stock traded hands, compared to its average volume of 334,772. The company has a market cap of $15.61 million, a price-to-earnings ratio of -0.11 and a beta of 2.42. The company has a fifty day moving average price of $6.47 and a two-hundred day moving average price of $7.97. Fractyl Health has a 52-week low of $1.11 and a 52-week high of $29.34. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. As a group, equities analysts predict that Fractyl Health will post -5.88 EPS for the current year.

Institutional Trading of Fractyl Health

A number of hedge funds have recently modified their holdings of GUTS. BlackRock Inc. acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $1,431,000. Bank of America Corp DE acquired a new position in Fractyl Health during the second quarter worth approximately $4,791,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $3,880,000. Pale Fire Capital SE lifted its stake in Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after purchasing an additional 2,711,103 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the second quarter valued at $8,968,058.

Fractyl Health Company Profile

(Get Free Report)

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.

Recommended Stories

Analyst Recommendations for Fractyl Health (NASDAQ:GUTS)

Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.